Key result
Sertraline significantly improved endothelial function, reduced inflammatory markers (CRP and IL-6), and decreased depression symptoms compared with placebo in patients with CHD.
Why the study?
Does sertraline improve endothelial function and reduce inflammatory markers in patients with coronary heart disease and symptoms of depression?
RCT (n=100)
Double-blind
randomized
Does sertraline improve endothelial function and reduce inflammatory markers in patients with coronary heart disease and symptoms of depression?
Sertraline therapy improves endothelial function and reduces inflammatory markers in patients with coronary heart disease and comorbid depression.
Supports sertraline for dual mood and vascular benefits in depressed CHD patients; extends RCT evidence to endothelial function and inflammation.
We investigated the effect of sertraline on inflammation and endothelial function in patients with coronary heart disease (CHD) and symptoms of depression. One hundred patients with CHD and depression were randomized in a double-blind fashion to receive sertraline or a placebo. We measured symptoms of depression (Beck Depression Inventory (BDI) score), levels of inflammatory markers (C-reactive protein (CRP) and interleukin-6 (IL-6)), and flow-dependent endothelium-mediated dilation (FMD) before and after 20 weeks of treatment. Sertraline treatment significantly reduced the BDI score as compared with both baseline and placebo. Levels of CRP and IL-6 also decreased after 20 weeks of sertraline treatment, whereas they did not significantly change in the placebo group. There was a significant improvement in FMD in patients on sertraline treatment, whereas there was no change in FMD in the placebo group. Sertraline improves endothelial function and reduces inflammatory markers in patients with CHD and symptoms of depression.
No takes yet. Share an insight, caveat, or question.
Pizzi et al. (2009) conducted an RCT in Coronary heart disease and depression (n=100). Sertraline vs. Placebo was evaluated on Symptoms of depression (BDI score), levels of inflammatory markers (CRP and IL-6), and flow-dependent endothelium-mediated dilation (FMD). Sertraline significantly improved endothelial function, reduced inflammatory markers (CRP and IL-6), and decreased depression symptoms compared with placebo in patients with CHD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: